Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Saved in:
Bibliographic Details
Title: Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.
Authors: Riecke A; German Military Hospital Ulm, Germany., Robrecht S; University Hospital of Cologne, Köln, Germany., Yosifov DY; German Cancer Research Center (DKFZ) Heidelberg, Germany., Schneider C; Ulm University, Ulm, Germany., Giza A; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany., Müller L; Studienzentrum UnterEms, Leer, Germany., Vehling-Kaiser U; Day Clinic Hematology Oncology Palliative Care., Eckart MJ; Hämatologie und Onkologie, Nürnberg, Germany., Freier W; Medicinum, Hildesheim, Alabama, Germany., Schöttker B; Hämatologisch-onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany., Gaska T; Brüderkrankenhaus St. Josef, Paderborn, Germany., Reiser M; PIOH, Cologne, Germany., Fink AM; University Hospital of Cologne, Cologne, Germany., Fischer K; University Hospital Cologne, Cologne, Germany., Eichhorst BF; University of Cologne, Cologne, Germany., Hallek MJ; University of Cologne, Cologne, Germany., Langerbeins P; University Hospital, Cologne, Germany., Stilgenbauer S; Ulm University, Ulm, Germany., Tausch E; Ulm University, Ulm, Germany.
Source: Blood [Blood] 2026 Jun 18. Date of Electronic Publication: 2026 Jun 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025032806